Firebrick Pharma (ASX:FRE) received notice of allowance of Nasodine's COVID-19 patent in Mexico, according to a Friday filing with the Australian bourse.
The patent protects the use of Nasodine nasal spray and any other intranasal povidone-iodine preparations as a method of reducing the viral load of SARS-CoV-2 in the nose, the filing stated.
The patent is already granted in the US, Australia, and South Africa, with applications in other countries still pending.
Firebrick Pharma's shares were up nearly 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments